Introduction
============

Hydrogen sulfide (H~2~S), the gas with "rotten egg" smell, has been recognized as the third bio-active gasotransmitter after nitric oxide and carbon monoxide. Mounting studies have revealed its protective effects in the cardiovascular system, central nervous system as well as in diabetes and inflammation. Besides the prominent role in metabolic regulation, recent reports have suggested that adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) also participates in various physiological and pathological processes and functions as a critical mediator in the effects of H~2~S. In this paper, we will review the latest and emerging evidences on AMPK-mediated therapeutic potentials of H~2~S.

Principles of H~2~S Biology
===========================

Biosynthesis of H~2~S
---------------------

For 100s of years H~2~S was thought to be noxious and toxic. What's interesting is that H~2~S and organosulfur compounds could be easily found in recipes, such as garlic products. Dietary garlic is well-known for its benefits in lowering blood pressure and lipid levels ([@B33]; [@B66]). In fact, [@B5] pointed out that garlic-derived organic polysulfides were converted rapidly by red blood cell into H~2~S, which was responsible for the subsequent vasorelaxation effects.

In addition to dietary consumption, H~2~S is endogenously produced as well. Physiological H~2~S production in mammal cells is mainly attributed to three enzymes, including cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-Mercaptopyruvate sulfurtransferase (3MST).

All these enzymes exhibit tissue-specific expression. CBS is expressed abundantly in the central nerves system, liver, kidney, and so on ([@B15]; [@B39]; [@B14]). It was believed that CSE was mainly produced in the cardiovascular system ([@B64]), but recent studies reported that CSE was also detected in the liver, lung, and kidney ([@B69]; [@B75]). 3MST was originally discovered in the brain of *Cbs* knockout mice ([@B67]), and further confirmed as a ubiquitous enzyme expressed in the lung, kidney, liver, and vasculature ([@B1]).

Moreover, these enzymes differ in cellular localization and H~2~S metabolism. CBS and CSE are localized in the cytosol, while 3MST is produced in both the cytosol and mitochondrial ([@B38]). In contrary to 3MST, CBS, and CSE are involved in multiple transsulfuration reactions, with pyridoxal 5′-phosphate as a cofactor and sulfur amino acids as substrates, including [L]{.smallcaps}-cysteine, [L]{.smallcaps}-cystine, and homocysteine ([@B46]). The H~2~S metabolism has been reviewed in detail elsewhere by [@B76].

Pharmacological Actions of H~2~S
--------------------------------

During the past decades, increasing studies have evidenced the functions of H~2~S in mammals, among which cardiovascular regulation is the most investigated ([@B64]). *Cse* knockout leads to severe hypertension in mice, suggesting H~2~S as a potential vasodilator ([@B86]). Indeed, similar to the other two gasotransmitters, both endogenous and exogenous-applied H~2~S exhibits vasorelaxation effects in multiple types of blood vessels ([@B41]). It was reported that the proliferation of vascular smooth muscle cell was inhibited by H~2~S, as opposed to vascular endothelial cells ([@B12]; [@B62]). Furthermore, H~2~S protects mice from myocardial infarction and ischemia-induced heart failure ([@B7]; [@B54]).

Apart from the cardiovascular system, H~2~S also contributes to protective effects in inflammation, oxidative stress, and nervous system. Despite the controversy regarding the multiple roles of H~2~S in inflammatory disorders, it is generally accepted that H~2~S ameliorates neuroinflammation, suppresses inflammatory cytokine production, and inhibits activation of key transcriptional factors. More details about the physiological and pharmacological functions of H~2~S could be found in reviews by [@B46] and [@B76].

AMPK and its Biological Function
================================

AMPK Regulation
---------------

Adenosine 5′-monophosphate-activated protein kinase is a conserved energetic sensor existed in almost all eukaryotes. Composed of a catalytic α-subunit and regulatory β- and γ-subunits, AMPK monitors intracellular AMP and adenosine triphosphate (ATP) levels ([@B34]; [@B47]). In mammals, APMKα catalytic subunits and β-subunits are encoded by two genes separately (α1, α2, and β1, β2), and γ-subunit by three genes (γ1, γ2, and γ3), making at least 12 possible heterotrimer combinations, of which the expression may be tissue restricted ([@B23]). For example, γ3 isoform is dominantly expressed in skeletal muscle, and both the wild type and a mutation of arginine to glutamine at position 225 (R225Q) in the CBS domain results in increased glycogen concentrations in skeletal muscle of the transgenic mice ([@B88]).

During energy deprivation characterized by increased AMP/ATP ratio, AMPK is phosphorylated at Thr172 and allosteric activated with a 100-fold increase in kinase activity ([@B24]). In mammals, the typical kinases involved in canonical AMPK activation include liver kinase B1 (LKB1) and Ca^2+^/calmodulin-activated protein kinase kinase β (CaMKKβ). LKB1, also known as a potent tumor suppressor, is vital for the basal phosphorylation level of AMPK ([@B23]). Genetic knockout of *LKB1* impairs AMPK activation by AMP, indicating its critical role during energy deprivation ([@B22]). AMPK is also activated in response to calcium flux, which relies on the intact function of CaMKKβ. It is noteworthy that this alternative AMPK activation pathway is independent of any change in cellular AMP level ([@B23]), and is most highlighted in the brain ([@B18]).

AMPK Activators
---------------

In addition to cellular metabolic signal, AMPK can be activated by a variety of compounds. AICAR (5-amino-4-imidazolecarboxamide riboside-1-β-[D]{.smallcaps}-ribofuranoside) is a potent AMPK activator. As an adenosine analog, AICAR is taken in by adenosine transporters and converted into ZMP (5-aminoimidazole-4-carboxamide-1-β-[D]{.smallcaps}-furanosyl 5′-monophosphate). Similar to AMP, ZMP binds directly to AMPK and induces its allosteric activation ([@B82]). Natural products and related derivatives represent another class of AMPK activators. Metformin, derived from French lilac, is widely administrated as the first-line medication for type 2 diabetes. Although the involved mechanisms remain partially understood, it is clear that AMPK plays an important role in the benefits of metformin ([@B92]). Resveratrol, isolated from grapes and red wine, is reported to activator AMPK and SIRT1, a NAD^+^-dependent protein deacetylase sharing crosstalk with AMPK ([@B65]). Other natural AMPK activators include epigallocatechin gallate, capsaicin, curcumin, berberine, and so on ([@B29]; [@B13]; [@B32]).

AMPK on Cellular Metabolism and More
------------------------------------

As a master cellular energy gauge, AMPK regulates lipid and glucose metabolism by phosphorylating downstream targets. Activated AMPK not only suppresses fatty acid synthesis by impairing acetyl-CoA carboxylase (ACC), but also facilitates lipid oxidation by boosting malonyl-CoA decarboxylase (MCD) ([@B89]; [@B90]). Similar regulating pattern is also observed in glucose metabolism. By promoting the translocation of glucose transporter 4 (GLUT4), AMPK activation stimulates glucose uptake in muscle tissue ([@B30]). In parallel, hepatic gluconeogenesis is inhibited by AMPK through decreased phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) transcription ([@B90]). In general, AMPK activation leads to metabolic changes toward relieving energy deprivation.

In addition to energy balance, recent studies have suggested the participation of AMPK in autophagy, atherosclerosis, inflammation, and cancer, which shares crosstalk with H~2~S ([@B57]; [@B36]; [@B60]). The advances in AMPK researches have shed light on novel therapeutic potentials of AMPK activators and H~2~S donors, and provided modern understanding of metabolism. More details will be discussed in the following sections.

AMPK in H~2~S Pharmacology
==========================

Great efforts have been made to elucidate the roles of AMPK in H~2~S pharmacology, in which AMPK usually serves as a key mediator. Despite the fact that AMPK was reported to be inhibited by H~2~S in some circumstances ([@B91]), it is generally accepted that H~2~S exerts its biological activity by activating AMPK. In this part we will review the recent discoveries on AMPK-H~2~S pharmacology.

AMPK in Cardioprotective Effects of H~2~S
-----------------------------------------

According to latest Global Burden of Disease Study, ischemic heart disease remained as the global leading cause for death in 2010, accounting for 13.3% of total death worldwide ([@B50]). A great number of patients are suffering from related diseases including ischemic heart failure and stable arrhythmia ([@B52]). The beneficial effects of H~2~S on survival after cardiac arrest in mice was first reported in 2009. By *i.v.* application of Na~2~S, an exogenous H~2~S donor, 7 min following cardiac arrest, significant increase in survival rate was achieved compared with vehicle ([@B56]). The authors pointed out that the treatment effects of Na~2~S was associated with activated AMPK prosurvival signals. In addition, AMPK is also attributed to the cardioprotective effects of H~2~S in high fat diet-induced cardiac dysfunction and impaired left ventricular function by smoking ([@B93]; [@B3]).

Myocardial ischemia/reperfusion (I/R) injury is a complication of inflammation and oxidative damage encountered when restoring blood supply of ischemic regions. Previous studies have demonstrated that H~2~S protects from I/R injury by multiple mechanisms, including ameliorating oxidative stress, inflammation, and apoptosis ([@B68]; [@B53]). [@B84] reported that AMPK is a critical mediator in the effects of H~2~S donor ADT. By maintaining autophagy flux impaired by I/R, as evidenced by reduced LC3-II/LC3-I ratio and beclin-1 expression, H~2~S-activated AMPK significantly relieved myocardial I/R injury.

Post-conditioning (PC), defined as brief repeated periods of ischemia performed at the onset of reperfusion, has been proved to reduce I/R injury in both cardiomyocytes and coronary vascular endothelium cells ([@B73]). Nevertheless PC only exerts cardioprotection in young but not old hearts ([@B6]). [@B10] suggested that by exogenous application of H~2~S, the treatment effects of PC could be restored in isolated aged rat hearts and aged cardiomyocytes. In contrast to the study on I/R, stimulated AMPK promoted autophagy, which subsequently decreased apoptosis, reduced myocardial injury, and improved cardiac function. More studies regarding AMPK-H~2~S and autophagy will be discussed in the next section.

AMPK-Regulated Autophagy in H~2~S Pharmacology
----------------------------------------------

Autophagy is a lysosome-dependent "self-engulfment" process in which cells digest their own cytosolic components to maintain metabolic homeostasis during starvation. Moreover, autophagy is tightly involved in cancer, cardiac and liver diseases ([@B45]). The autophagy pathway was originally discovered with Atg1/UNC-51-like kinase (ULK) 1 complex as an essential initiator, which also senses cellular nutrient status from the mammalian target of rapamycin (mTOR). Previous studies have established the prominent role of AMPK in regulating autophagy. One of the most described mechanism involves the suppression of mTOR pathway by AMPK, which promotes the formation of autophagosomes ([@B37]). On the other hand, AMPK directly phosphorylates several critical sites in ULK1 and subsequently induces its activation in autophagy and mitochondrial homeostasis ([@B21]). By inhibiting mTOR and activating ULK1, AMPK regulates autophagy in response to nutritional signal ([@B55]).

The AMPK-autophagy pathway has been identified in multiple pharmacological functions of H~2~S. As described in the last section, H~2~S mitigates cardiac I/R injury and restores PC protection by regulating AMPK-mediated autophagy. Similar results were also observed in high glucose conditions. Vascular endothelial dysfunction induced by hyperglycemia impairs vasodilation and angiogenic function, leading to diabetic complications ([@B26]). Exogenous H~2~S markedly preserved arterial endothelial cells by reducing AMPK phosphorylation and inhibiting excessive autophagy ([@B48]). Furthermore, [@B42] suggested that H~2~S relieved renal matrix accumulation during hyperglycemia by LKB1/AMPK cascade. Intriguingly, as opposed to the previous study, AMPK was activated by H~2~S, leading to protective autophagy in glomerular endothelial cells ([@B42]).

Hypertriglyceridemia is among the most common metabolic diseases and is proved as an independent risk factor for cardiovascular and cerebrovascular events ([@B9]). Lower plasma H~2~S content was reported to be associated with dyslipidemia, indicating the potential regulation of H~2~S on serum triglyceride ([@B49]). Indeed, [@B70] claimed that H~2~S reduced triglyceride and relieved non-alcoholic fatty liver disease in mice by activating AMPK and inhibiting mTOR. Consistent regulation of AMPK and autophagy by H~2~S was reported in inhibiting colon epithelial cell proliferation ([@B83]).

AMPK in H~2~S Protection against Diabetic Complications
-------------------------------------------------------

Chronic hyperglycemia of diabetes leads to damage and dysfunction of multiple organs, including the kidney, heart, and blood vessels ([@B2]). The anti-diabetic effects of AMPK activators are well-documented, and numerous evidences have indicated the mitigation of hyperglycemia and related complications by H~2~S ([@B71]; [@B72]). [@B44], [@B43]) suggested that H~2~S decreased protein synthesis, cellular hypertrophy, and matrix protein accumulation of renal cells under high glucose condition. Moreover, H~2~S inhibited mTOR activity, mRNA initiation and elongation by activating AMPK through CaMKKβ. Corresponding AMPK/mTOR regulation by H~2~S was also reported in cardiomyocyte protection from high glucose ([@B77]).

Vascular inflammation induced by hyperglycemia is associated with impaired insulin sensitivity and accelerated atherosclerosis ([@B4]; [@B61]). Both [L]{.smallcaps}-cysteine, the endogenous precursor of H~2~S, and exogenous H~2~S donors successfully diminished high glucose-stimulated inflammatory cytokine secretion from monocytic cells, indicating the link between H~2~S and vascular inflammation ([@B31]). It was further supported that H~2~S relieved vascular inflammation via multiple mechanisms including activating AMPK ([@B51]). These findings might bring light on the therapeutic potentials of H~2~S against diabetic complications.

AMPK in Anti-inflammatory and Anti-oxidant Stress Properties of H~2~S
---------------------------------------------------------------------

There have been controversies over the exact role of H~2~S in inflammation ([@B80]). Despite distinct results obtained, it appears that the inconsistency in the pro- and anti-inflammatory effects of H~2~S might be attributed to models, doses, and sampling time ([@B25]). It is generally acknowledged that H~2~S shows remarkable suppression on lipopolysaccharide-induced production of inflammatory cytokines both in macrophages and microglia cells ([@B28]; [@B79]). In parallel, the inhibition of inflammation by AMPK activation has been also been reported ([@B60]). [@B94] found that the suppression of microglia inflammation by H~2~S was largely dependent on AMPK activation via CaMKKβ pathway, which was evidenced by multiple H~2~S donors, CBS overexpression, and *AMPK* knockdown.

Anemia of inflammation (AI) is the second prevalent anemia and a common complication in patients with chronic diseases ([@B78]). Lower hemoglobin is associated with increased mortality in diseases such as heart failure ([@B27]; [@B59]), cancer ([@B8]), and chronic kidney disease ([@B16]; [@B74]). The pathological changes of AI include iron disturbance and erythroid system dysfunction ([@B58]), of which iron dysregulation is the hallmark. Mounting evidences have indicated that elevated hepatic and circulating hepcidin, a liver-derived iron-regulating peptide, is tightly involved in the progression of AI ([@B17]), making it an ideal target for AI treatment. We first reported that during inflammation H~2~S inhibited hepatic hepcidin, a critical factor in AI pathogenesis ([@B85]). Our recent investigation revealed that the effects of H~2~S was partially mediated by AMPK ([@B75]). What's more, both pharmacological and genetic activation of AMPK, as well as metformin, ameliorated chronic AI in mice, which was supported by our clinical samples and independent groups ([@B35]; [@B75]). Interestingly, metformin was reported to increase H~2~S content in various mouse tissues ([@B81]). Much more work will be needed to broaden our understanding about the interaction among H~2~S, AMPK and metformin.

5′-Monophosphate-activated protein kinase also contributes to the effects of H~2~S and garlic products against oxidant stress. [@B20] claimed that ajoene, a garlic by-product, reduced oxidative injury and hepatic steatosis by stimulating LKB1/AMPK pathway. Consistent results were observed in H~2~S donors. Sodium hydrosulfide, an inorganic H~2~S donor, ameliorated oxidative stress and apoptosis via activating CaMKKβ/AMPK signaling, finally attenuating experimental aging process ([@B11]). Furthermore, reactive oxygen species production was diminished by H~2~S-induced AMPK activation in osteoblast cells treated with dexamethasone ([@B87]).

Current Research Gaps
=====================

It is of great importance to understand the specific mechanisms within H~2~S-induced AMPK activation. However, few studies have looked into this topic. Kundu colleagues claimed that H~2~S activated AMPK by LKB1 (see section "AMPK in Cardioprotective Effects of H~2~S"), while Lee colleagues (see section "AMPK-Regulated Autophagy in H~2~S Pharmacology") and Zhou colleagues (see section "AMPK in H~2~S Protection against Diabetic Complications") suggested CaMKKβ was indispensable for AMPK activation by H~2~S.

It is worth noting that instead of fully elucidating the potential mechanisms, all these studies mainly pointed out several key mediators in the H~2~S-AMPK pathway. Moreover, recent studies have revealed that H~2~S might also regulate protein functions in a more "direct" manner, such as by sulfhydration ([@B63]) and forming polysulfides ([@B19]; [@B40]). Future studies may help better understand the role of these novel modifications in H~2~S-AMPK interactions.

Conclusion
==========

In summary, this minireview provides novel insights into latest AMPK-mediated H~2~S pharmacology in various tissues and diseases (**Figure [1](#F1){ref-type="fig"}**). Despite substantial progress, there remains a long road toward complete understanding of AMPK-H~2~S interactions and application of H~2~S donors in clinical settings.

![A schematic diagram of multiple roles of AMPK in the pharmacological functions of H~2~S. AMPK, adenosine 5′-monophosphate-activated protein kinase; H~2~S, hydrogen sulfide; LKB1, liver kinase B1; CaMKKβ, Ca^2+^/calmodulin-activated protein kinase kinase β; mTOR, mammalian target of rapamycin; ULK2, UNC-51-like kinase 2; TG, triglyceride; I/R, ischemia/reperfusion; PC, post-conditioning; ROS, reactive oxygen species.](fphar-08-00810-g001){#F1}
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